Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 10/20 | 0.45 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7544383 | 1.00 | ACE (0.51) | ACEACE2FKBP1AMMEL1ITGB1 | |
| SCHEMBL7540635 | 0.95 | ACE (0.50) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL7537880 | 0.93 | ACE (0.52) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL8739522 | 0.90 | ACE (0.49) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL6119591 | 0.88 | MMEL1 (0.57) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL7538528 | 0.88 | MMEL1 (0.57) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL6119582 | 0.88 | MMEL1 (0.57) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL7537478 | 0.88 | MMEL1 (0.53) | ACEACE2FKBP1AMMEL1 | |
| SCHEMBL7539217 | 0.87 | ACE (0.51) | ACEFKBP1AMMEL1TSHR | |
| SCHEMBL6119055 | 0.87 | ACE (0.51) | ACEFKBP1AMMEL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | ACE 7/4885ACE2 29/4885FKBP1A 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.